Vaxcyte shares are trading. higher after the company announced topline results from the OPUS-1 pivotal adult Phase 3 trial. Vax-31 met all prespecified primary endpoints across age groups studied.

Benzinga Newsdesk www.benzinga.com Positive 93.9%

Neg 0% Neu 0% Pos 93.9%

Comments

No comments yet. Be the first!